{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T04:07:16Z","timestamp":1774930036944,"version":"3.50.1"},"reference-count":35,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Oncology: Seminars and Original Investigations"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1016\/j.urolonc.2022.06.007","type":"journal-article","created":{"date-parts":[[2022,7,10]],"date-time":"2022-07-10T07:04:23Z","timestamp":1657436663000},"page":"491.e1-491.e9","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["A longitudinal single center analysis of T1HG bladder cancer: An 18 year experience"],"prefix":"10.1016","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7210-7558","authenticated-orcid":false,"given":"Courtney","family":"Yong","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah L.","family":"Mott","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryan L.","family":"Steinberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vignesh T.","family":"Packiam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael A.","family":"O'Donnell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.urolonc.2022.06.007_bib0001","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/j.juro.2016.06.049","article-title":"Diagnosis and treatment of non-muscle invasive bladder cancer: AUA\/SUO guideline","volume":"196","author":"Chang","year":"2016","journal-title":"J Urol"},{"issue":"5","key":"10.1016\/j.urolonc.2022.06.007_bib0002","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/j.eururo.2018.06.024","article-title":"Treatment strategy for newly diagnosed T1 high-grade bladder urothelial carcinoma: New insights and updated recommendations","volume":"74","author":"Klaassen","year":"2018","journal-title":"Eur Urol"},{"issue":"3","key":"10.1016\/j.urolonc.2022.06.007_bib0003","doi-asserted-by":"crossref","first-page":"329","DOI":"10.6004\/jnccn.2020.0011","article-title":"Bladder cancer, version 3.2020, NCCN clinical practice guidelines in oncology","volume":"18","author":"Flaig","year":"2020","journal-title":"J Natl Compr Canc Netw"},{"issue":"5","key":"10.1016\/j.urolonc.2022.06.007_bib0004","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/j.eururo.2019.08.016","article-title":"European association of urology guidelines on non-muscle-invasive bladder cancer (TaT1 and Carcinoma In Situ) - 2019 update","volume":"76","author":"Babjuk","year":"2019","journal-title":"Eur Urol"},{"issue":"16","key":"10.1016\/j.urolonc.2022.06.007_bib0005","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1200\/JCO.2015.64.4070","article-title":"Definitions, end points, and clinical trial designs for non-muscle-invasive bladder cancer: Recommendations from the international bladder cancer group","volume":"34","author":"Kamat","year":"2016","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.urolonc.2022.06.007_bib0006","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/S0022-5347(05)67281-3","article-title":"The 3-month clinical response to intravesical therapy as a predictive factor for progression in patients with high risk superficial bladder cancer","volume":"164","author":"Solsona","year":"2000","journal-title":"J Urol"},{"issue":"4","key":"10.1016\/j.urolonc.2022.06.007_bib0007","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1016\/S0022-5347(05)65756-4","article-title":"Does early cystectomy improve the survival of patients with high risk superficial bladder tumors?","volume":"166","author":"Herr","year":"2001","journal-title":"J Urol"},{"issue":"22","key":"10.1016\/j.urolonc.2022.06.007_bib0008","doi-asserted-by":"crossref","first-page":"5525","DOI":"10.1002\/cncr.27587","article-title":"The long-term outcome of treated high-risk nonmuscle-invasive bladder cancer: Time to change treatment paradigm?","volume":"118","author":"Thomas","year":"2012","journal-title":"Cancer"},{"key":"10.1016\/j.urolonc.2022.06.007_bib0009","doi-asserted-by":"crossref","DOI":"10.1007\/s00345-018-2450-0","article-title":"Predictors of oncological outcomes in T1G3 patients treated with BCG who undergo radical cystectomy","author":"Soria","year":"2018","journal-title":"World J Urol"},{"issue":"1","key":"10.1016\/j.urolonc.2022.06.007_bib0010","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.eururo.2014.06.040","article-title":"Prognostic factors and risk groups in T1G3 non-muscle-invasive bladder cancer patients initially treated with Bacillus Calmette-Guerin: results of a retrospective multicenter study of 2451 patients","volume":"67","author":"Gontero","year":"2015","journal-title":"Eur Urol"},{"issue":"2","key":"10.1016\/j.urolonc.2022.06.007_bib0011","doi-asserted-by":"crossref","first-page":"215","DOI":"10.3233\/BLC-150039","article-title":"Bacillus Calmette-Guerin (BCG) treatment failures with non-muscle invasive bladder cancer: A data-driven definition for BCG unresponsive disease","volume":"2","author":"Steinberg","year":"2016","journal-title":"Bladder Cancer"},{"issue":"11","key":"10.1016\/j.urolonc.2022.06.007_bib0012","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1089\/end.2011.0081","article-title":"Repeated white light transurethral resection of the bladder in nonmuscle-invasive urothelial bladder cancers: Systematic review and meta-analysis","volume":"25","author":"Vianello","year":"2011","journal-title":"J Endourol"},{"issue":"5","key":"10.1016\/j.urolonc.2022.06.007_bib0013","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1016\/S0022-5347(05)01002-5","article-title":"The effect of repeat transurethral resection on recurrence and progression rates in patients with T1 tumors of the bladder who received intravesical mitomycin: A prospective, randomized clinical trial","volume":"175","author":"Divrik","year":"2006","journal-title":"J Urol"},{"issue":"5","key":"10.1016\/j.urolonc.2022.06.007_bib0014","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1016\/j.juro.2017.11.096","article-title":"Efficacy and safety of blue light flexible cystoscopy with hexaminolevulinate in the surveillance of bladder cancer: A phase III, comparative, multicenter study","volume":"199","author":"Daneshmand","year":"2018","journal-title":"J Urol"},{"issue":"1","key":"10.1016\/j.urolonc.2022.06.007_bib0015","doi-asserted-by":"crossref","first-page":"65","DOI":"10.3233\/BLC-150008","article-title":"Sequential intravesical gemcitabine and docetaxel for the salvage treatment of non-muscle invasive bladder cancer","volume":"1","author":"Steinberg","year":"2015","journal-title":"Bladder Cancer"},{"issue":"18","key":"10.1016\/j.urolonc.2022.06.007_bib0016","doi-asserted-by":"crossref","first-page":"2729","DOI":"10.1200\/JCO.2005.05.2720","article-title":"Phase II trial of intravesical gemcitabine in bacille calmette-guerin-refractory transitional cell carcinoma of the bladder","volume":"24","author":"Dalbagni","year":"2006","journal-title":"J Clin Oncol"},{"issue":"19","key":"10.1016\/j.urolonc.2022.06.007_bib0017","doi-asserted-by":"crossref","first-page":"3075","DOI":"10.1200\/JCO.2005.03.1161","article-title":"Phase I trial of intravesical docetaxel in the management of superficial bladder cancer refractory to standard intravesical therapy","volume":"24","author":"McKiernan","year":"2006","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.urolonc.2022.06.007_bib0018","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/j.juro.2011.03.129","article-title":"A phase I trial of intravesical nanoparticle albumin-bound paclitaxel in the treatment of bacillus calmette-guerin refractory nonmuscle invasive bladder cancer","volume":"186","author":"McKiernan","year":"2011","journal-title":"J Urol"},{"issue":"11","key":"10.1016\/j.urolonc.2022.06.007_bib0019","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1111\/j.1442-2042.2012.03089.x","article-title":"Role of routine transurethral biopsy and isolated upper tract cytology after intravesical treatment of high-grade non-muscle invasive bladder cancer","volume":"19","author":"Lightfoot","year":"2012","journal-title":"Int J Urol"},{"issue":"1","key":"10.1016\/j.urolonc.2022.06.007_bib0020","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1186\/s12957-018-1497-0","article-title":"Bladder preservation approach versus radical cystectomy for high-grade non-muscle-invasive bladder cancer: A meta-analysis of cohort studies","volume":"16","author":"Shen","year":"2018","journal-title":"World J Surg Oncol"},{"issue":"2","key":"10.1016\/j.urolonc.2022.06.007_bib0021","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1097\/JU.0000000000000919","article-title":"A Phase I trial of intravesical cabazitaxel, gemcitabine and cisplatin for the treatment of nonmuscle invasive bacillus calmette-guerin unresponsive or recurrent\/relapsing urothelial carcinoma of the bladder","volume":"204","author":"DeCastro","year":"2020","journal-title":"J Urol"},{"issue":"2","key":"10.1016\/j.urolonc.2022.06.007_bib0022","doi-asserted-by":"crossref","first-page":"e20","DOI":"10.1016\/j.urolonc.2021.07.019","article-title":"Long-term efficacy of hyperthermic intravesical chemotherapy for BCG-unresponsive non-muscle invasive bladder cancer","volume":"40","author":"Pijpers","year":"2022","journal-title":"Urol Oncol"},{"issue":"7","key":"10.1016\/j.urolonc.2022.06.007_bib0023","doi-asserted-by":"crossref","first-page":"e8","DOI":"10.1016\/j.urolonc.2021.01.004","article-title":"The association of salvage intravesical therapy following BCG with pathologic outcomes and survival after radical cystectomy for patients with high-grade non-muscle invasive bladder cancer: A multi-institution analysis","volume":"39","author":"Packiam","year":"2021","journal-title":"Urol Oncol"},{"issue":"4","key":"10.1016\/j.urolonc.2022.06.007_bib0024","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1007\/s11255-011-9941-x","article-title":"T1G3 high-risk NMIBC (non-muscle invasive bladder cancer): Conservative treatment versus immediate cystectomy","volume":"43","author":"De Berardinis","year":"2011","journal-title":"Int Urol Nephrol"},{"issue":"3","key":"10.1016\/j.urolonc.2022.06.007_bib0025","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1007\/s00345-009-0402-4","article-title":"Quantification of the survival benefit of early versus deferred cystectomy in high-risk non-muscle invasive bladder cancer (T1 G3)","volume":"27","author":"Hautmann","year":"2009","journal-title":"World J Urol"},{"issue":"4","key":"10.1016\/j.urolonc.2022.06.007_bib0026","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1016\/j.juro.2006.11.090","article-title":"Treatment paradigm shift may improve survival of patients with high risk superficial bladder cancer","volume":"177","author":"Raj","year":"2007","journal-title":"J Urol"},{"issue":"3","key":"10.1016\/j.urolonc.2022.06.007_bib0027","doi-asserted-by":"crossref","first-page":"127","DOI":"10.4103\/0974-7796.84960","article-title":"Survival after primary and deferred cystectomy for stage T1 transitional cell carcinoma of the bladder","volume":"3","author":"Ali-El-Dein","year":"2011","journal-title":"Urol Ann"},{"issue":"3","key":"10.1016\/j.urolonc.2022.06.007_bib0028","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1200\/JCO.2001.19.3.666","article-title":"Radical cystectomy in the treatment of invasive bladder cancer: Long-term results in 1,054 patients","volume":"19","author":"Stein","year":"2001","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.urolonc.2022.06.007_bib0029","doi-asserted-by":"crossref","first-page":"267","DOI":"10.5489\/cuaj.5039","article-title":"Recurrence and upstaging rates of T1 high-grade urothelial carcinoma of the bladder on repeat resection in a Canadian, resource-limited, healthcare system","volume":"12","author":"Kinnaird","year":"2018","journal-title":"Can Urol Assoc J"},{"issue":"10","key":"10.1016\/j.urolonc.2022.06.007_bib0030","doi-asserted-by":"crossref","DOI":"10.3390\/jcm9103306","article-title":"Restaging transurethral resection of bladder tumours after BCG immunotherapy induction in patients with T1 non-muscle-invasive bladder cancer might not be associated with oncologic benefit","volume":"9","author":"Krajewski","year":"2020","journal-title":"J Clin Med"},{"key":"10.1016\/j.urolonc.2022.06.007_bib0031","doi-asserted-by":"crossref","first-page":"465","DOI":"10.3389\/fonc.2019.00465","article-title":"Is repeat transurethral resection always needed in high-grade T1 bladder cancer?","volume":"9","author":"Calo","year":"2019","journal-title":"Front Oncol"},{"issue":"8","key":"10.1016\/j.urolonc.2022.06.007_bib0032","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1089\/end.2020.0301","article-title":"The impact of restaging transurethral resection of bladder tumor on survival parameters in T1 nonmuscle-invasive bladder cancer: Systematic review and meta-analysis","volume":"34","author":"Krajewski","year":"2020","journal-title":"J Endourol"},{"issue":"1","key":"10.1016\/j.urolonc.2022.06.007_bib0033","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1111\/bju.15166","article-title":"Prospective evaluation of blue-light flexible cystoscopy with hexaminolevulinate in non-muscle-invasive bladder cancer","volume":"127","author":"Lotan","year":"2021","journal-title":"BJU Int"},{"issue":"1","key":"10.1016\/j.urolonc.2022.06.007_bib0034","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.juro.2007.03.034","article-title":"A phase III, multicenter comparison of hexaminolevulinate fluorescence cystoscopy and white light cystoscopy for the detection of superficial papillary lesions in patients with bladder cancer","volume":"178","author":"Grossman","year":"2007","journal-title":"J Urol"},{"issue":"1","key":"10.1016\/j.urolonc.2022.06.007_bib0035","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.juro.2007.03.028","article-title":"A comparison of hexaminolevulinate fluorescence cystoscopy and white light cystoscopy for the detection of carcinoma in situ in patients with bladder cancer: A phase III, multicenter study","volume":"178","author":"Fradet","year":"2007","journal-title":"J Urol"}],"container-title":["Urologic Oncology: Seminars and Original Investigations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143922002265?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143922002265?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T10:25:18Z","timestamp":1761042318000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1078143922002265"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":35,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2022,11]]}},"alternative-id":["S1078143922002265"],"URL":"https:\/\/doi.org\/10.1016\/j.urolonc.2022.06.007","relation":{},"ISSN":["1078-1439"],"issn-type":[{"value":"1078-1439","type":"print"}],"subject":[],"published":{"date-parts":[[2022,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A longitudinal single center analysis of T1HG bladder cancer: An 18 year experience","name":"articletitle","label":"Article Title"},{"value":"Urologic Oncology: Seminars and Original Investigations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urolonc.2022.06.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}